Background: Patients with immune-mediated disorders such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and rheumatoid arthritis are increasingly treated with tumor necrosis factor (TNF) inhibitors. The safety of anti-TNF therapy in patients with a history of cancer requires further evaluation. We conducted a systematic review and a meta-analysis of observational studies including patients with a history of cancer exposed to anti-TNF therapy assessing for a risk of new cancer or cancer recurrence.
T umor necrosis factor (TNF) inhibitors are commonly utilized medications for the treatment of immunemediated conditions including ankylosing spondylitis, inflammatory bowel disease (IBD), psoriasis, and rheumatoid arthritis (RA). 1, 2 Chimeric, partly humanized, or fully human monoclonal antibodies or antibody fragments have been compared with placebo in randomized controlled trials and have demonstrated efficacy for the management of IBD, 3 psoriasis, 4 and RA. 5 Given the efficacy of the anti-TNF biological therapies in immune-mediated disorders, studies have previously sought to quantify the risks of therapy to include cardiovascular disease, 6 the development of plaque psoriasis, 7 infection, 3 and malignancy. 8 However, randomized controlled trials of TNF inhibitors have excluded individuals with a past history of cancer, limiting the evidence for the use of anti-TNF therapy in such individuals.
There is evidence suggesting that immune suppression is associated with malignancy. This has been described in primary (congenital) immune deficiencies, 9, 10 human immunodeficiency virus/acquired immune deficiency syndrome, [11] [12] [13] [14] [15] and immune suppressing medical therapies. 16, 17 Studies have also assessed the role of TNF inhibitors in the development of incident cancer, 8, [18] [19] [20] [21] but its role in patients with a history of cancer has not been sufficiently reviewed. 22, 23 Current guidelines from the American College of Gastroenterology 24 and American Gastroenterological Association 25 do not provide specific recommendations for the use of anti-TNF therapy in individuals with a prior history of cancer whereas the European Crohn's and Colitis Organization (ECCO) consensus statement recommends delaying the resumption of immunosuppressant therapy for 2 years following the completion of cancer treatment, and extending to 5 years if the cancer is associated with an intermediate or high risk of recurrence. 26 The American College of Rheumatology recommends starting or resuming biological therapy for patients treated for a solid malignancy >5 years prior. 27 As patients with immune-mediated conditions continue to age, the lifetime risk of cancer progressively increases because of increases in life expectancy and increased age-specific rates of various cancers. 28 Combined with the improved prognosis of individuals with a history of cancer, physicians increasingly will be faced with the challenge of managing patients with a history of cancer and chronic noncommunicable illnesses. To provide evidence for the management of immune-mediated disorders in individuals with a history of cancer, we conducted a systematic review and a meta-analysis of cohort and casecontrol studies assessing for a risk of new cancer or cancer recurrence in individuals with a history of cancer and exposed to anti-TNF therapy.
MATERIALS AND METHODS
Our meta-analysis followed the reporting recommendations proposed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 29 The protocol of this meta-analysis has not been published or registered to any databases.
Data Sources
We performed a computerized literature search of EMBASE (1947 to September 
Search Strategy and Study Selection
To be eligible for inclusion, we only considered: (1) a study designed as case-control or cohort study, (2) evaluating the association between cancer recurrence and anti-TNF therapy, (3) including >10 patients exposed to anti-TNF therapy, and (4) reporting an incidence rate ratio (IRR) or hazard ratio with 95% confidence intervals (CIs) utilizing a comparison group in which participants were not exposed to anti-TNF therapy. Comparator groups included those exposed to and not exposed to immunomodulatory therapy. There were no restrictions regarding age, sex, and duration of study. Case series and review articles were excluded. We imposed no geographic or language restrictions and articles in languages other than English were translated if necessary. Two authors (D.M. and A.A.) independently screened each of the potential titles, abstracts, and/or full-manuscripts to determine whether they were eligible for inclusion. Areas of disagreement or uncertainty were resolved by consensus between the 2 authors. The corresponding authors of studies were contacted to provide additional information on studies if required.
Studies were identified in the literature review with the terms: malignancy or cancer and recurrence. These were combined by using the set operator AND with studies identified with the terms: infliximab, Remicade, monoclonal antibody cA2, adalimumab, Humira, certolizumab pegol, golimumab, Simponi, etanercept, Enbrel, Cimzia, CDP-870, tumour necrosis factor, tumor necrosis factor, anti-tumour necrosis, anti-tumor necrosis, anti-TNF, and TNF alpha antibody 30 as free-text terms.
Data Extraction and Quality Assessment
All data were independently extracted in duplicate by 2 authors (D.M. and A.S.) using a data extraction form. Data on the study characteristics, such as author name, year of publication, country, cohort size, mean age of patients, underlying inflammatory condition, underlying cancer, development of new cancer or cancer recurrence, follow-up and interval between cancer, and anti-TNF use were collected. Where available, the use of concomitant immunosuppressant therapy was recorded. Studies that reported events without a comparator group were excluded from analysis. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of studies. 31 A total score of Z7 was defined as a high quality study and a total score of r6 was defined as a low quality study.
Outcome Assessment
The primary outcome assessed was the development of a new cancer or cancer recurrence while on anti-TNF therapy compared with utilization of nonbiological therapies. Where available the use of immunosuppressive therapy in the control group was recorded.
Data Synthesis and Analysis
Direct random-effects meta-analysis was performed to assess the risk of new or recurrent cancer diagnosis with anti-TNF therapies. Pooled incidence rates were compiled and an IRR for cancer development with 95% CIs, was used to express differences in therapy.
The result of individual studies is expected to be diverse; therefore this inconsistency was quantified with a statistical test of heterogeneity. This quantity, termed I 2 , ranges from 0% to 100%, with 0% representing no observed heterogeneity, and larger values indicating increasing heterogeneity. A value of r25%, accompanied by a P-value of >0.10 for the w 2 test, was arbitrarily chosen to represent low levels of heterogeneity. 3 To address significant heterogeneity, we used a sequential approach to explore whether specific studies accounted for the observed heterogeneity. 32 To assess the potential for publication bias and smallstudy effect, we performed Begg and Egger test and constructed funnel plots to visualize possible asymmetry when Z3 studies were available. 33, 34 We performed a priori subgroup analysis according to disease type (IBD vs. RA), underlying cancer diagnosis (solid tumor malignancy, skin cancer, and all cancers excluding skin cancer), time to initiation of anti-TNF therapy and study quality as assessed by the NOS score. All statistical analyses were performed with Comprehensive Meta-Analysis V2 (Biostat; Englewood, NJ). P-values that were <0.05 were considered statistically significant. All statistical tests were 2-sided.
RESULTS
The search strategy identified 4425 citations, of which 4292 records were excluded after examining the title and abstract. A total of 92 studies were retrieved and evaluated in detail. Fifty-five studies evaluating the development of incident cancers in individuals without a history of cancer were excluded. Eight records utilizing overlapping registries, [35] [36] [37] [38] [39] [40] [41] [42] 3 studies evaluating the progression of premalignant conditions, [43] [44] [45] 15 case reports or case series that lacked a comparator group, 46-60 and 2 studies including <10 patients exposed to anti-TNF therapy 61, 62 were excluded from the analysis (Fig. 1) .
Included in the meta-analysis were 9 studies 41,63-70 reporting on 10 populations with inflammatory disorders. Six of the studies were from Europe and 3 were from the United States. Eight populations evaluated the risk of cancer development among individuals with a history of rheumatic disease 41, [64] [65] [66] [67] [68] [69] [70] and 2 evaluated the risk of new cancer or cancer recurrence among individuals with a history of IBD. 63, 69 No included studies evaluated the risk of cancer recurrence in a population with psoriasis. Multicenter and registry studies included cases of all previous cancers, 41, 63, 64, 70 skin cancer [melanoma and non-melanoma skin cancer (NMSC)], 41, [63] [64] [65] [66] 69 and only solid tumor cancers: breast cancer 68 and head and neck cancer. 67 The duration interval between original cancer diagnosis and initiation of anti-TNF therapy ranged from 1.2 years to 11.5 years in reported studies. The characteristics and outcomes of the included studies are summarized in Table 1 .
Study quality is reported in Table 2 . All studies scored well on patient selection and most studies scored well on comparability of the cohorts. Outcome assessments were more variable with poor documentation of overall follow-up.
Overall Risk of New Cancer or Cancer Recurrence with anti-TNF Therapy
The 9 studies included a total of 11,679 patients with a history of cancer. Of these, 3707 individuals were exposed to anti-TNF therapy following a cancer diagnosis and 7972 were exposed to no immunosuppression or nonbiological disease modifying therapy. In total, there were 298 new cancers or cancer recurrences among individuals exposed to anti-TNF therapy and 625 new or recurrent cancers in the control groups. The pooled incidence rates of cancer development were 3.2 per 100 patient-years (95% CI, 2. 1-4.9) in the anti-TNF exposed group and 3.6 of 100 patient-years (95% CI, 2.3-5.6) in the control cohort.
Two study populations included patients with a history of IBD and did not demonstrate an increased risk of new or recurrent cancer (IRR, 0.68; 95% CI, 0.40-1.16).
Eight study populations included patients with a history of arthritis or RA without a demonstrated increased risk of new or recurrent cancer (IRR, 1.06; 95% CI, 0.78-1.46).
The pooled IRR of new or recurrent cancer among individuals with a history of cancer exposed to anti-TNF therapy was not significantly different compared with control therapies (IRR, 0.90; 95% CI, 0.59-1.37) (Fig. 2) . Significant heterogeneity was seen (I 2 = 55.94%; P = 0.015) in the pooled analysis. Visual inspection of the funnel plot demonstrated no asymmetry and there was no publication bias as assessed by Begg and Egger test (P = 0.86, 0.78, respectively). Significant heterogeneity was not observed in the subgroup of individuals with IBD (I 2 = 0%; P = 0.39), but was observed in the subgroup with a history of arthritis or RA (I 2 = 53.23%; P = 0.036). This heterogeneity was primarily driven by the study by SilvaFernandez et al. 70 Exclusion of this study yielded a similar pooled IRR (0.95; 95% CI, 0.52-1.73) with lower heterogeneity in the subgroup including individuals with arthritis or RA (I 2 = 0%; P = 0.59) as well as in the pooled analysis (I 2 = 42.47%; P = 0.08) (Appendix Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/JCG/A337). Figure 3 shows the IRR for each secondary outcome with respect to the underlying cancer diagnosis (solid tumor malignancy, skin cancer, all cancers excluding skin cancer). In the a priori subgroup analysis, the IRR of new cancer or cancer recurrence was not increased for individuals with a history of solid tumor malignancy (0.72; 95% CI, 0.37-1.39) with no heterogeneity between studies (I 2 = 9.83%; P = 0.33) and without evidence of funnel plot asymmetry (Egger test, P = 0.77). 63, 67, 68 Among individuals with a prior history of skin cancer, new or recurrent cancer was not increased (0.89; 95% CI, 0.34-2.28). 41, 63, 65, 66, 69 Heterogeneity between studies was significant (I 2 = 69.75%; P = 0.005) and was without evidence of funnel plot asymmetry (Egger test, P = 0.77). When all skin cancers were excluded in a subgroup analysis, no significant increased risk of new or recurrent cancer was demonstrated (0.80; 95% CI, 0.55-1.16) with heterogeneity demonstrated between studies (I 2 = 63.24%; P = 0.018) and without evidence of funnel plot asymmetry (Egger test, P = 0.55). 41, 63, 64, 67, 68, 70 
Subgroup Analysis by Cancer Type

Subgroup Analysis by Time to anti-TNF Initiation
Among studies initiating anti-TNF therapy >5 years after cancer diagnosis, there was no increased risk of cancer recurrence (IRR, 0.84; 95% CI, 0.51-1.38) 41, 68, 70 (Fig. 4) . This was similar to the studies not reporting the time to anti-TNF exposure (IRR, 1.11; 95% CI, 0.79-1.56) [64] [65] [66] [67] 69 and the single study reporting a median time to anti-TNF exposure of 1.2 years (IRR, 0.58; 95% CI, 0.28-1.23). 63 Among studies initiating anti-TNF therapy >5 years after cancer diagnosis, heterogeneity was significantly increased (I 2 = 60.45%; P = 0.00), which decreased (I 2 = 0%; P = 1.00) when excluding the prior study by SilvaFernandez. Visual inspection of the funnel plot did not demonstrate asymmetry and there was no publication bias as assessed by Begg and Egger test (P = 1.00, 0.37, respectively). new cancer or cancer recurrence among studies with a NOS score of Z7 (IRR, 0.84; 95% CI, 0.56-1.26). 63, 64, 66, 68, 70 There was no evidence of significant heterogeneity (I 2 = 58.53%; P = 0.065) and no evidence of funnel plot asymmetry (Egger test, P = 0.35). This was similar to the studies with a NOS score of r6 (IRR, 1.06; 95% CI, 0.72-1.58), 41, 65, 67, 69 
DISCUSSION
We performed a systematic review and a meta-analysis of observational studies to evaluate the risk of new cancer development or cancer recurrence among individuals with a history of previous cancer and subsequently exposed to anti-TNF therapy. We found that the risk of new or recurrent cancer among individuals with a history of cancer exposed to anti-TNF therapy was not significantly different compared with control therapies. We have demonstrated that patients with a history of cancer are not at an increased risk of developing a new or recurrent cancer when exposed to anti-TNF therapy when compared with a comparator population receiving nonbiological disease modifying therapies. In terms of individual cancer types studied, there were no obvious differences in risk of new cancer development or cancer recurrence among individuals with a history of solid tumor malignancy, skin cancer, or when examining the subgroup excluding skin cancers.
As the initial pooled analysis demonstrated significant heterogeneity, a sequential exclusion approach was used to identify studies contributing to the observed heterogeneity. Exclusion of the study by Silva-Fernandez et al 70 led to a decrease in heterogeneity of the pooled analysis. When excluded from the subgroup analysis limited to individuals with RA and arthritis, the pooled incidence of new cancer or cancer recurrence increased in individuals exposed to anti-TNF therapy (RR, 1.27; 95% CI, 1.01-1.60). Although exclusion of a study demonstrating a decreased incidence of incident cancer diagnosis with anti-TNF therapy is expected to alter the results of a subgroup analysis, the study by Silva-Fernandez et al 70 is not an outlier with respect to methodology as a second included study from the British Society for Rheumatology Biologics Register was included in pooled analysis assessing risk of skin cancer. 65 The mechanism by which immunosuppressants promote cancer includes direct alterations of DNA in cells, reduced immunosurveillance for tumor cells, or impaired immunosurveillance for chronic infection by mutagenic viruses. 71 Among individuals with IBD exposed to thiopurine therapies, increased risks of NMSC, lymphoma, and myeloid disorders have been demonstrated, [72] [73] [74] with decreased risks of lymphoma development after drug discontinuation. 72, 75 The initial isolation of TNF in 1975 and gene cloning in 1984 stemmed from early observations of the role of bacterial extracts in necrosis of sarcoma tumors. 76 Ultimately, Carswell et al 77 reported on a factor isolated in the serum of Bacillus Calmette-Guerin (BCG)-infected mice made by host cells in response to endotoxin in which the term was coined "tumor necrosis factor." Further studies evaluated the role of TNF in human tumors, although recombinant TNF administration was associated with severe toxicities. 76 With further research into the tumor microenvironment and evidence of cancer-related inflammation and the proliferation and survival of malignant cells, the role of anti-TNF therapy has been studied in a number of active malignancies to include management of AZA/6MP indicates azathioprine/6-mercaptopurine; IBD, inflammatory bowel disease; IMM, immunomodulator; IRR, incidence rate ratio; MTX, methotrexate; nbDMARD, nonbiological disease-modifying antirheumatic drug; NMSC, non-melanoma skin cancer; NR, not reported; NSAID, nonsteroidal anti-inflammatory drug; RA, rheumatoid arthritis; TNF, tumor necrosis factor. ovarian cancer, 78 bladder cancer, 79 advanced/metastatic solid cancer, 80 cancer-related cachexia, 81 and in the prevention of graft-versus host disease 82 demonstrating biological safety without significant risk of cancer progression.
Previous studies have evaluated the risk of incident cancer development among individuals exposed to anti-TNF therapy. In an early meta-analysis of data from randomized controlled trials utilizing anti-TNF therapy in individuals 8 , demonstrated a dose-dependent increased risk of malignancy among individuals exposed to anti-TNF therapy (pooled odds ratio, 3.3; 95% CI, 1.2-9.1). However, the initial meta-analysis suggesting an increased risk of incident cancer development was critiqued citing an unexpectedly low rate of malignancy in the control arms of the meta-analysis, the use of an odds ratio to compare malignancy risk as opposed to incidence rates, therefore assuming equality of patient follow-up, as well as inclusion of malignancy diagnosed within 6 weeks of therapy initiation. 83 Subsequent observational registry studies evaluating incident cancer development among individuals with RA exposed to anti-TNF therapy and linked to the Swedish Cancer Registry failed to demonstrate an increased risk of incident cancer development compared with biologic-naive comparator populations (RR, 1.00; 95% CI, 0.86-1.15). 20 A meta-analysis demonstrated a pooled estimate for the risk of incident cancer from 7 studies without a significantly increased risk of all-site malignancy (RR, 0.95; 95% CI, 0.73-1.51) among patients with RA, psoriatic arthritis, or ankylosing spondylitis. 84 Furthermore, the risk of lymphoma was not increased (RR, 1.11; 95% CI, 0.70-1.51) whereas risks of NMSC (RR, 1.45; 95% CI, 1.15-1.76) and melanoma (RR, 1.79; 95% CI, 0.92-2.67) were increased among individuals exposed to anti-TNF therapies in 4 studies and 2 studies, respectively. 84 Although the risk of incident cancer development among individuals exposed to anti-TNF therapy does not seem to be increased compared with comparator populations, when cancers develop, previous studies have demonstrated high rates of discontinuation of anti-TNF therapy. 53 When cancer develops among individuals exposed to anti-TNF therapies, a nationwide study evaluating cancer stage at diagnosis and risk of death following a diagnosis of cancer, no increased risk of death was demonstrated among individuals developing cancer whereas on anti-TNF therapy compared with a biologics-naive control group. 85 Although the biology of cancers developing in individuals exposed to anti-TNF therapy is not more aggressive, a cancer diagnosis is a common reason for anti-TNF therapy discontinuation, with increased rates of discontinuation among the elderly.
The risk of second cancer among individuals with a history of cancer is increased compared with the general population. An analysis of the SEER Program found that cancer survivors had a 14% higher risk of developing a new malignancy that would be expected in the general population (observed/expected, 1.14; 95% CI, 1.14-1.15). 86 A more recent study from the Netherlands evaluating the development of second cancers among individuals with a history of Hodgkin lymphoma demonstrated again a 4.6-fold increased risk of second cancer compared with the expected rate from the general population with a cumulative incidence of second cancer of 48.5% at 40 years of follow-up. 87 With respect to individuals with a history of IBD, an analysis from the CESME study group identified 405 patients with a history of cancer among 17,047 patients included in a prospective observational study. Although not included in this metaanalysis as only 7 patients with a history of cancer were exposed to anti-TNF therapy, the primary finding included an increased risk of cancer among those with a previous history of cancer (adjusted hazard ratio, 1.9; 95% CI, 1.2-3.0; P = 0.003). 61 No significant associations were demonstrated between individuals exposed to immunosuppressant therapy and the risk of cancer development among individuals with a history of cancer.
A recent meta-analysis and systematic review combining the incidence rates of cancer recurrence among individuals with a history of cancer and immunosuppression exposure was performed demonstrating similar results to include a pooled cancer incidence rate of 33.8 per 1000 person-years among individuals receiving anti-TNF therapy and 37.5 per 1000 person-years among individuals not receiving immunosuppressive therapy. 88 Our study demonstrates similar findings with the pooled incidence rates of cancer development being 3.2 per 100 patient-years in the anti-TNF exposed group and 3.6 per 100 patient-years in the control cohort (which includes immunomodulator exposure). Although both metaanalyses include several overlapping studies, our study adds to the current literature with the inclusion of several individual reports related to cancer recurrence not included in the prior meta-analysis resulting in increased power. 64, 65, 67 The strengths of our study include our ability to combine studies to include over 3500 individuals with a history of cancer exposed to anti-TNF therapy, a sample size difficult to obtain utilizing national databases or multicenter studies. Although subgroup analyses limit the power of a conclusion, we did not find differing risks of cancer recurrence among the baseline cancer subtypes including solid tumors and skin cancers. Our meta-analysis showed no publication bias, which strengthens the results of our study.
The limitations of our meta-analysis include the inclusion of only observational studies; however, the quality of the included studies was good. Randomized controlled trials have commonly excluded patients with a history of cancer, therefore requiring the use of observational studies to assess the risk of adverse events among patients with a history of cancer. Studies of risk factors generally cannot be randomized because they relate to inherent human characteristic or practices, and exposing subjects to potential harmful risk factors is unethical. 89 Limitations of use of observational studies include selection bias between the individuals selected to be exposed to anti-TNF therapy compared with those remaining on nonbiological disease modifying medications. 90 A selection bias would require patients exposed to anti-TNF therapy to have a lower risk of cancer recurrence, whereas control populations remain at a higher risks of cancer development, therefore masking a potentially increased risk of cancer recurrence among individuals exposed to anti-TNF therapy. Secondly, short durations of follow-up can limit the detection of new or recurrent cancers; however, this was limited by including person-years of exposure to normalize follow-up time between anti-TNF and control groups. Lastly, different cancers have different intrinsic cancer recurrence risks based on innate biology and stage at the time of original diagnosis. We attempted to perform subgroup analysis to explore risks of cancer recurrence among differing etiologies of cancer without differences in recurrence risk dependent on anti-TNF therapy.
In conclusion, this meta-analysis including 10 study populations and over 3500 patients with a history of anti-TNF use after cancer diagnosis demonstrates the safety of anti-TNF therapy among individuals with a history of cancer, without a demonstrated risk for the development of new or recurrent cancer compared with nonbiological disease modifying therapies. Given the prolonged interval between cancer diagnosis and anti-TNF initiation in most studies, care should still be taken with a multidisciplinary approach to adequately discuss with the patient and treating physician risk of individual disease recurrence and the known risks and benefits of anti-TNF therapy for modifying clinical disease activity. Further large scale observational studies will be required to assess clinical factors associated with cancer recurrence in the variety of cancer subtypes to adequately understand factors predisposing to recurrence in patients requiring disease modifying therapy for active inflammatory disorders.
